Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 20/20 | 0.66 |
| ▸ | KCNH2 | Q12809 | 15/20 | 0.66 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5316946 | 0.84 | MCHR1 (0.72) | MCHR1KCNH2 | |
| SCHEMBL4922168 | 0.82 | MCHR1 (0.75) | MCHR1KCNH2CYP3A4 | |
| Chlorolithium SCHEMBL4927355 | 0.82 | MCHR1 (0.68) | MCHR1KCNH2 | |
| Chlorolithium SCHEMBL4927349 | 0.82 | MCHR1 (0.68) | MCHR1KCNH2 | |
| SCHEMBL4923666 | 0.81 | MCHR1 (0.61) | MCHR1KCNH2CYP3A4 | |
| SCHEMBL4923604 | 0.81 | MCHR1 (0.67) | MCHR1KCNH2CYP3A4 | |
| SCHEMBL4926494 | 0.81 | MCHR1 (0.73) | MCHR1KCNH2CYP3A4 | |
| SCHEMBL4922155 | 0.80 | MCHR1 (0.69) | MCHR1KCNH2 | |
| SCHEMBL4923586 | 0.80 | MCHR1 (1.00) | MCHR1KCNH2 | |
| SCHEMBL4927631 | 0.80 | MCHR1 (0.65) | MCHR1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080306055-A1 | Heterocyclic Mchr1 Antagonists And Their Use In Therapy | ASTRAZENECA AB (SE) | 2008-12-11 | — | — | US | claimed |
| EP-1831194-A1 | HETEROCYCLIC MCHr1 ANTAGONISTS AND THEIR USE IN THERAPY | AstraZeneca AB (SE) | 2007-09-12 | — | — | EP | claimed |
| WO-2006068594-A1 | HETEROCYCLIC MCHr1 ANTAGONISTS AND THEIR USE IN THERAPY | ASTRAZENECA AB (SE) | 2006-06-29 | — | — | WO | claimed |
| US-20080306055-A1 | Heterocyclic Mchr1 Antagonists And Their Use In Therapy | ASTRAZENECA AB (SE) | 2008-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306055-A1 | Heterocyclic Mchr1 Antagonists And Their Use In Therapy | MCHR1, MCHR2, MC1R | MCHR1 1/4885KCNH2 1440/4885CYP3A4 968/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.